echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > NEJM: Daprodustat treats anemia in chronic kidney disease undergoing dialysis

    NEJM: Daprodustat treats anemia in chronic kidney disease undergoing dialysis

    • Last Update: 2021-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chronic kidney disease (CKD) undergoing dialysis treatment of most patients with anemia, resulting in patient quality of life is reduced, frequent blood transfusions and cardiac vascular events increased risk
    .


    Previous studies have found that traditional erythropoietin (ESAs) treatment is associated with an increased risk of cardiovascular events in patients, while recombinant human erythropoietin and its derivatives may increase the risk of stroke, myocardial infarction , thrombosis, and tumor in patients


    Quality of life of heart vascular events myocardial infarction thrombosis recently researchers examined Daprodustat anemia of CKD patients undergoing dialysis efficacy and safety


    In this randomized, open phase 3 trial, CKD patients undergoing dialysis with a hemoglobin level of 8.
    0 to 11.
    5 g/dL were randomized to receive Daprodustat or ESAs (hemodialysis patients received epoetin alfa, and peritoneal dialysis patients received alfada Bettin)
    .


    The primary endpoint of the study was the average change in hemoglobin levels from baseline examination to weeks 28-52 and the first major adverse cardiovascular event (combination of death from any cause, non-fatal myocardial infarction, or non-fatal stroke)


    2964 patients participated in the study, and the average baseline hemoglobin level was 10.
    4 g/dL
    .


    The average change in hemoglobin level from baseline inspection to week 28 to week 52 in the Daprodustat group was 0.


    The average change in hemoglobin levels in the Daprodustat group from baseline inspection to week 28 to week 52 was 0.


    Changes in hemoglobin levels between groups

    Changes in hemoglobin levels between groups Changes in hemoglobin levels between groups

    In CKD patients undergoing dialysis, Daprodustat is comparable to erythropoiesis agents in improving hemoglobin levels and cardiovascular outcomes


    In CKD patients undergoing dialysis, Daprodustat is equivalent to erythropoiesis agents in increasing hemoglobin levels and cardiovascular outcomes.


    Original source:

    Ajay K.


    Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.